Amgen is delighted to announce the launch of the
PCSK9 Competitive Grant Program
, which will provide an opportunity for investigators from around the world to compete for individual grants of up to 200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.
The program is global in reach and is open to proposals from established and junior investigators*.
The deadline for applications is Friday, May 11, 2018 (11:59 pm US Pacific Time).
*Junior investigators should be within 5 years of completion of training
Information Notice:
The information on this page is intended for scientific, educational, and general informational purposes. Clinical approaches, availability, and regulatory status may vary by country, institution, and medical indication. For individual medical decisions, readers should consult qualified healthcare professionals and accredited medical centers.
The information on this page is intended for scientific, educational, and general informational purposes. Clinical approaches, availability, and regulatory status may vary by country, institution, and medical indication. For individual medical decisions, readers should consult qualified healthcare professionals and accredited medical centers.
Editorial Note:
This article has been prepared by the NBScience editorial team within the scope of clinical research, biotechnology, and international medical information.
This article has been prepared by the NBScience editorial team within the scope of clinical research, biotechnology, and international medical information.
